The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Geneoscopy
Develops non-invasive, stool-based RNA tests to detect colorectal cancer and precancerous lesions.
What they do
Geneoscopy designs non-invasive screening diagnostics utilizing eukaryotic RNA biomarkers isolated from stool samples. Clinicians and gastroenterologists use its ColoSense test to detect colorectal cancer and high-risk adenomas early, avoiding or prioritizing subsequent colonoscopy screening procedures.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- St. Louis, United States
- Region
- North America
- Founded
- 2015
- Total funding
- $115M raised
Notable investors: Lightstone Ventures, Sect-37, Cultivation Capital, RiverVest Venture Partners.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The barbershop health screening model is expanding well beyond blood pressure
Dr. Dereck Mush, MD, MBA
Screening Programs Are Rebuilding Around Reminder Systems That Actually Reach People
Dr. Dereck Mush, MD, MBA
PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA